Fluoropyrimidine
Sponsors
University of Alabama at Birmingham, Sanofi, Nanfang Hospital, Southern Medical University, National Cancer Institute (NCI), Centre Hospitalier Universitaire Dijon
Conditions
Autoimmune DiseaseColon Cancer MetastaticColorectal CancerCrohn DiseaseDermatomyositisGI CancersHematopoietic and Lymphoid Cell NeoplasmInflammatory Bowel Disease
Phase 1
Phase 2
BMS-247550 in Treating Patients With Metastatic Colorectal Cancer
TerminatedNCT00033306
Start: 2002-02-28End: 2005-07-31Updated: 2013-08-05
TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer
CompletedNCT00399750
Start: 2002-11-30End: 2005-06-30Target: 373Updated: 2009-10-15
Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies
Enrolling by invitationNCT06648785
Start: 2024-10-21End: 2026-11-01Target: 20Updated: 2026-02-05
Phase 3
Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis
NCT03023436
Start: 2016-01-31End: 2022-06-30Target: 220Updated: 2019-09-13
A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer
NCT04188145
Start: 2020-01-27End: 2025-12-31Target: 400Updated: 2021-10-28
A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma
Active, not recruitingNCT04257461
Start: 2020-02-20End: 2025-12-31Target: 30Updated: 2025-02-06
Unknown Phase
Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study
Enrolling by invitationNCT04260269
Start: 2018-06-01End: 2027-12-31Target: 200Updated: 2024-12-12
Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC
Active, not recruitingNCT07494578
Start: 2025-07-01End: 2027-08-01Target: 300Updated: 2026-03-27